跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

870295P

Avanti

DSPE-RGD

Avanti Research™ - A Croda Brand 870295P, powder

别名:

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)

登录查看公司和协议定价

选择尺寸

1 MG
$513.00

$513.00

请联系客服了解存货情况
获取大包装报价
所有图片(1)

选择尺寸

变更视图
1 MG
$513.00

About This Item

经验公式（希尔记法）:
C68H120N9Na2O18PS
CAS号:
2260795-79-5
分子量:
1460.75
UNSPSC代码:
12352211
NACRES:
NA.25

$513.00

请联系客服了解存货情况
获取大包装报价

表单

powder

包装

pkg of 1 × 1 mg (870295P-1mg)

制造商/商品名称

Avanti Research™ - A Croda Brand 870295P

应用

advanced drug delivery

运输

dry ice

储存温度

−20°C

SMILES字符串

[H][C@@](COP([O-])(OCCNC(C1CCC(CN2C(CC(SC[C@@H](C([O-])=O)NC([C@H](CC([O-])=O)NC(CNC([C@@H]([NH3+])CCCNC(N)=N)=O)=O)=O)C2=O)=O)CC1)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.[Na+].[Na+]

InChI

1S/C68H122N9O18PS.2Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-35-61(82)92-48-53(95-62(83)36-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)49-94-96(90,91)93-43-42-72-63(84)52-39-37-51(38-40-52)47-77-59(79)45-57(66(77)87)97-50-56(67(88)89)76-65(86)55(44-6

InChI key

BNMYYFNFRONMOH-CIJOWSANSA-L

生化/生理作用

Arginine-glycine-aspartic acid (RGD) modified liposomes show potential for cancer research.

包装

5 mL Amber Glass Screw Cap Vial (870295P-1mg)

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

储存分类代码

11 - Combustible Solids

闪点(°F)

No data available

闪点(°C)

No data available

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Cheng-Wei Chen et al.
International journal of nanomedicine, 6, 2567-2580 (2011-12-01)
Human retinal pigment epithelial cells are promising target sites for small interfering RNA (siRNA) that might be used for the prevention and/or treatment of choroidal neovascularization by inhibiting the expression of angiogenic factor; for example, by downregulating expression of the
Yunjie Cao et al.
International journal of clinical and experimental medicine, 8(8), 12182-12191 (2015-11-10)
In this study, we report an active targeting liposomal formulation directed by a novel peptide (RGD) that specifically binds to the integrins receptors overexpressed on prostatic cancer cells. The objectives of this study were to evaluate the in vitro and

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持